ZA964373B - A pharmaceutical composition for treating lukemia - Google Patents

A pharmaceutical composition for treating lukemia

Info

Publication number
ZA964373B
ZA964373B ZA964373A ZA964373A ZA964373B ZA 964373 B ZA964373 B ZA 964373B ZA 964373 A ZA964373 A ZA 964373A ZA 964373 A ZA964373 A ZA 964373A ZA 964373 B ZA964373 B ZA 964373B
Authority
ZA
South Africa
Prior art keywords
lukemia
treating
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
ZA964373A
Inventor
James B Camden
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of ZA964373B publication Critical patent/ZA964373B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
ZA964373A 1995-06-07 1996-05-29 A pharmaceutical composition for treating lukemia ZA964373B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47381795A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
ZA964373B true ZA964373B (en) 1996-09-02

Family

ID=23881113

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA964373A ZA964373B (en) 1995-06-07 1996-05-29 A pharmaceutical composition for treating lukemia

Country Status (17)

Country Link
EP (1) EP0831816A1 (en)
JP (1) JPH11506732A (en)
KR (1) KR19990022617A (en)
CN (1) CN1186433A (en)
AR (1) AR003137A1 (en)
AU (1) AU717382B2 (en)
BR (1) BR9608730A (en)
CA (1) CA2223435A1 (en)
CZ (1) CZ391197A3 (en)
HU (1) HUP9802634A3 (en)
IL (1) IL118424A0 (en)
NO (1) NO975660L (en)
PL (1) PL324026A1 (en)
SK (1) SK168697A3 (en)
TR (1) TR199701536T1 (en)
WO (1) WO1996040122A1 (en)
ZA (1) ZA964373B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) * 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
EP2251010A1 (en) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Use of thiabendazole and derivatives thereof for the therapy of neurological conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL134354C (en) * 1963-05-23
FR2155888A1 (en) * 1971-10-13 1973-05-25 Agot Aime Solid anthelmintic composn - for more economical treatment of ruminants

Also Published As

Publication number Publication date
AR003137A1 (en) 1998-07-08
BR9608730A (en) 1999-06-29
AU717382B2 (en) 2000-03-23
PL324026A1 (en) 1998-05-11
CZ391197A3 (en) 1998-05-13
HUP9802634A3 (en) 1999-05-28
HUP9802634A2 (en) 1999-03-29
AU5802096A (en) 1996-12-30
CN1186433A (en) 1998-07-01
TR199701536T1 (en) 1998-02-21
NO975660D0 (en) 1997-12-05
JPH11506732A (en) 1999-06-15
SK168697A3 (en) 1998-12-02
CA2223435A1 (en) 1996-12-19
IL118424A0 (en) 1996-09-12
EP0831816A1 (en) 1998-04-01
WO1996040122A1 (en) 1996-12-19
NO975660L (en) 1998-02-09
KR19990022617A (en) 1999-03-25

Similar Documents

Publication Publication Date Title
HUP9802086A3 (en) Pharmaceutical composition for piperidinoalkanol compounds
HU9601698D0 (en) Pharmaceutical composition
EP0850057A4 (en) Pharmaceutical compounds
ZA964373B (en) A pharmaceutical composition for treating lukemia
ZA962214B (en) Pharmaceutical composition
GB9519667D0 (en) Pharmaceutical composition
ZA963590B (en) Pharmaceutical composition
ZA9610426B (en) Pharmaceutical composition
GB9502695D0 (en) Pharmaceutical composition
ZA964193B (en) Pharmaceutical composition
SG47206A1 (en) Pharmaceutical compounds
AU7295696A (en) Pharmaceutical composition for treating osteoporosis
ZA963591B (en) Pharmaceutical composition
HU9602822D0 (en) Pharmaceutical composition
ZA95736B (en) Pharmaceutical composition
ZA963388B (en) A pharmaceutical composition
HUP9602732A3 (en) Pharmaceutical composition comprising lanperisone
ZA961389B (en) Pharmaceutical composition for piperidinoalkanol compounds
SI0812195T1 (en) Pharmaceutical composition for piperidinoalkanol compounds
GB9506273D0 (en) Pharmaceutical compounds
GB9526437D0 (en) Pharmaceutical compounds
GB9517866D0 (en) Pharmaceutical compounds
GB9517867D0 (en) Pharmaceutical compounds
GB9522132D0 (en) Pharmaceutical compounds
GB9517865D0 (en) Pharmaceutical compounds